Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
Mulling biopharma’s Minority Report moment
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.